Abstract
This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Aged
-
Aged, 80 and over
-
Androstenes / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Biomarkers, Tumor / genetics
-
Humans
-
Male
-
Nitriles
-
Phenylthiohydantoin / analogs & derivatives*
-
Phenylthiohydantoin / therapeutic use
-
Prostatic Neoplasms, Castration-Resistant / drug therapy*
-
Prostatic Neoplasms, Castration-Resistant / genetics
-
Protein Isoforms / genetics
-
Receptors, Androgen / genetics*
-
Treatment Outcome
-
Tumor Suppressor Protein p53 / genetics
Substances
-
AR protein, human
-
Androstenes
-
Antineoplastic Agents
-
Benzamides
-
Biomarkers, Tumor
-
Nitriles
-
Protein Isoforms
-
Receptors, Androgen
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
Phenylthiohydantoin
-
enzalutamide
-
abiraterone